Effectiveness and safety of drotrecogin alfa (activated) for severe sepsis: A meta-analysis and metaregression

The Lancet Infectious Diseases

Volumn 12, Issue 9, 2012, Pages 678-686

  Kalil, Andre C ^a   LaRosa, Steven P ^b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Beverly Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

ARTICLE; BLEEDING; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; SEPSIS; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFECTIVE AGENTS; DRUG TOXICITY; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84865278685     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70157-3     Document Type: Article

References (47)

1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29:1303-1310.
2. Martin GS, Mannino DM, Eaton S, Moss M The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003, 348:1546-1554.
3. Hall MJ, Williams SN, DeFrances CJ, Golosinskiy A Inpatient care for septicemia or sepsis: a challenge for patients and hospitals. NCHS Data Brief 2011, 62:1-8.
4. Riewald M, Ruf W Protease-activated receptor-1 signaling by activated protein C in cytokine-perturbed endothelial cells is distinct from thrombin signaling. J Biol Chem 2005, 280:19808-19814.
5. Della Valle P, Pavani G, D'Angelo A The protein C pathway and sepsis. Thromb Res 2012, 129:296-300.
6. Taylor FB, Chang A, Esmon CT, D'Angelo A, Vigano-D'Angelo S, Blick KE Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J Clin Invest 1987, 79:918-925.
7. Murakami K, Okajima K, Uchiba M, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood 1996, 87:642-647.
8. Li W, Zheng X, Gu J, et al. Overexpressing endothelial cell protein C receptor alters the hemostatic balance and protects mice from endotoxin. J Thromb Haemost 2005, 3:1351-1359.
9. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709. the Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group.
10. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003, 31:12-19. the PROWESS Investigators.
11. Warren HS, Suffredini AF, Eichacker PQ, Munford RS Risks and benefits of activated protein C treatment for severe sepsis. N Engl J Med 2002, 347:1027-1030.
12. Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005, 353:1332-1341. the Administration of Drotrecogin Alfa (Activated) in Early Stage Severe Sepsis (ADDRESS) Study Group.
13. Marti-Carvajal AJ, Sola I, Lathyris D, Cardona AF Human recombinant activated protein C for severe sepsis. Cochrane Database Syst Rev 2012, 3. CD004388.
14. Kalil AC, Sun J Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A Bayesian analysis. PLoS One 2008, 3:e2291.
15. Finfer S, Ranieri VM, Thompson BT, et al. Design, conduct, analysis and reporting of a multi-national placebo-controlled trial of activated protein C for persistent septic shock. Intensive Care Med 2008, 34:1935-1947.
16. Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012, 366:2055-2064. the PROWESS-SHOCK Study Group.
17. DerSimonian R, Laird N Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
18. Higgins JP, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses. BMJ 2003, 327:557-560.
19. Sterne JA, Gavaghan D, Egger M Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 2000, 53:1119-1129.
20. Kübler A, Mayzner-Zawadzka E, Durek G, et al. Results of severe sepsis treatment program using recombinant human activated protein C in Poland. Med Sci Monit 2006, 12:CR107-CR112.
21. Bertolini G, Rossi C, Anghileri A, Livigni S, Addis A, Poole D Use of Drotrecogin alfa (activated) in Italian intensive care units: the results of a nationwide survey. Intensive Care Med 2007, 33:426-434.
22. Dhainaut JF, Payet S, Vallet B, et al. Cost-effectiveness of activated protein C in real-life clinical practice. Crit Care 2007, 11:R99. the PREMISS Study Group.
23. Rowan KM, Welch CA, North E, Harrison DA Drotrecogin alfa (activated): real-life use and outcomes for the UK. Crit Care 2008, 12:R58.
24. Vincent JL, Laterre PF, Decruyenaere J, et al. A registry of patients treated with drotrecogin alfa (activated) in Belgian intensive care units-an observational study. Acta Clin Belg 2008, 63:25-30.
25. Martin G, Brunkhorst FM, Janes JM, et al. The international PROGRESS registry of patients with severe sepsis: drotrecogin alfa (activated) use and patient outcomes. Crit Care 2009, 13:R103.
26. Ferrer R, Artigas A, Suarez D, et al. Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational study. Am J Respir Crit Care Med 2009, 180:861-866. the Edusepsis Study Group.
27. Lindenauer PK, Rothberg MB, Nathanson BH, Pekow PS, Steingrub JS Activated protein C and hospital mortality in septic shock: a propensity-matched analysis. Crit Care Med 2010, 38:1101-1107.
28. Sadaka F, O'Brien J, Migneron M, Stortz J, Vanston A, Taylor RW Activated protein C in septic shock: a propensity-matched analysis. Crit Care 2011, 15:R89.
29. Hecksher CA, Lacerda HR, Maciel MA Characteristics and outcomes of patients treated with drotrecogin alpha and other interventions of the " Surviving Sepsis" campaign in clinical practice. RBTI 2008, 20:135-143.
30. Wheeler A, Steingrub J, Schmidt GA, et al. A retrospective observational study of drotrecogin alfa (activated) in adults with severe sepsis: comparison with a controlled clinical trial. Crit Care Med 2008, 36:14-23.
31. Higgins TL, Steingrub JS, Tereso GJ, Tidswell MA, McGee WT Drotrecogin alfa (activated) in sepsis: initial experience with patient selection, cost, and clinical outcomes. J Intensive Care Med 2005, 20:339-345.
32. Bollinger J, Coley K, Rea R, Saul M Outcomes in patients with recombinant human activated protein c at an academic medical center versus the ENHANCE US trial. Crit Care Med 2006, 34:A111.
33. Spriet I, Meersseman W, Wilmer A, Meyfroidt G, Casteels M, Willems L Evaluation of drotrecogin alpha use in a Belgian university hospital. Pharm World Sci 2006, 28:290-295.
34. Eli Lilly. An open label study of drotrecogin alfa (activated) in adult patients with severe sepsis and multiple organ dysfunctions, a phase IV protocol. 2006; Summary ID 7159: 1-6.
35. Ridley S, Lwin A, Wyncoll D, et al. Drotrecogin alfa (activated): diffusion from clinical trials to clinical practice. Eur J Anaesthesiol 2008, 25:211-216.
36. Kanji S, Perreault MM, Chant C, Williamson D, Burry L Evaluating the use of drotrecogin alfa (activated) in adult severe sepsis: a Canadian multicenter observational study. Intensive Care Med 2007, 33:517-523.
37. Ernst FR, Johnston JA, Pulgar S, et al. Timing of drotrecogin alfa (activated) initiation in treatment of severe sepsis: a database cohort study of hospital mortality, length of stay, and costs. Curr Med Res Opin 2007, 23:235-244.
38. Macchiavello L, Ellis G, Bowden S, Smithies M A large, single-centre UK registry of drotrecogin alfa-activated use. Crit Care 2007, 11(suppl 2):58.
39. Decruyenaere J, De Backer D, Spapen H, et al. 90-day follow-up of patients treated with drotrecogin alfa (activated) for severe sepsis: a Belgian open label study. Acta Clin Belg 2009, 64:16-22.
40. Anger K, DeGrado J, Greenwood B, Szumita P Evaluation of recombinant activated protein C in severe sepsis at a tertiary academic medical center. Crit Care Med 2009, 37:A235.
41. Gentry CA, Gross KB, Sud B, Drevets DA Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit Care Med 2009, 37:19-25.
42. Steingrub JS, Cheatham ML, Woodward B, Wang HT, Effron MB A prospective, observational study of Xigris use in the United States (XEUS). J Crit Care 2010, 25:660.e9. for the XEUS investigators, 660.16.
43. Maurice A, Seguin P, Aguillon D, Chanavaz C, Mallédant Y Activated protein C treatment: experience about 23 patients in the operative period. Ann Fr Anesth Reanim 2005, 24:343-346.
44. Vincent JL, Bernard GR, Beale R, et al. Drotrecogin alfa (activated) treatment in severe sepsis from the global open-label trial ENHANCE: further evidence for survival and safety and implications for early treatment. Crit Care Med 2005, 33:2266-2277.
45. Kalil AC Does recombinant activated protein C work in patients with severe sepsis?. Crit Care Med 2010, 38:1217-1220.
46. Casserly B, Gerlach H, Phillips GS, Marshall JC, Lemeshow S, Levy MM Evaluating the use of recombinant human activated protein C in adult severe sepsis: results of the Surviving Sepsis Campaign. Crit Care Med 2012, 40:1417-1426.
47. Kalil AC, LaRosa SP, Gogate J, Lynn M, Opal SM Influence of severity of illness on the effects of eritoran tetrasodium (E5564) and on other therapies for severe sepsis. Shock 2011, 36:327-331. the Eritoran Sepsis Study Group.